Dynavax Technologies Corp. 8-K Filing Highlights Major Shareholder Events

Based on the provided section of the financial report, here are the key extracted insights:

Entity Information:

Company Name: Dynavax Technologies Corp.
CIK Number: 0001029142 (Unique identifier for the company by the SEC).
Address: 2100 Powell Street Suite 720, Emeryville, CA 94608.
Phone Number: 510-848-5100.
Stock Exchange: Common Stock traded on NASDAQ under the ticker symbol DVAX.

Report Type and Date:

Filing Type: 8-K (a current report used to announce major events that shareholders should know about).
Filing Date: December 26, 2024.

Stock Information:

Class of Stock: Common Stock with a par value of $0.001.
Preferred Stock: Indicates existence of Preferred Stock and associated share purchase rights.

Contextual Information:

The report refers to specific periods and classes of stock but does not provide quantitative financial data in the snippet. The context IDs suggest that there are segments for both Common Stock and Preferred Stock.

Regulatory Context:

The report is filed under the US GAAP (Generally Accepted Accounting Principles) for the year 2024, indicating it adheres to standardized financial reporting guidelines.

Insights:

The filing indicates an important corporate event or change that might affect shareholders or investors, which necessitated the 8-K filing.
The presence of both Common and Preferred Stock suggests potential complexities in the capital structure, which may affect shareholder equity and dividends.
Investors should look out for further details in the 8-K filing to understand the implications of the reported events.

In summary, this snippet provides foundational information about Dynavax Technologies Corp., including its stock structure and the nature of the filing, but does not include specific financial metrics or substantive changes that would typically be found in a complete 8-K filing. Further analysis of the full report would be necessary to uncover detailed insights.